Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Surgery Partners (NASDAQ:SGRY) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Surgery Partners and provided 12-month price targets. The average target is $18.2, accompanied by a high estimate of $21.00 and a low estimate of $14.00. A 23.53% drop is evident in the current average compared to the previous average price target of $23.80.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Surgery Partners. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| A.J. Rice | UBS | Lowers | Buy | $21.00 | $29.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $17.00 | $19.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $20.00 | $31.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $14.00 | $18.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $19.00 | $22.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Surgery Partners. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Surgery Partners compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Surgery Partners's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Surgery Partners's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Surgery Partners analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Surgery Partners Better
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
Surgery Partners's Economic Impact: An Analysis
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Surgery Partners's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.63% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Surgery Partners's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surgery Partners's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.31%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.29%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Surgery Partners's debt-to-equity ratio is below the industry average. With a ratio of 2.24, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment